| INTRODUCTION

This is our fifth consecutive year of selecting what we, the Editors of
Prenatal Diagnosis, believe were some of the key publications in the field of prenatal diagnosis and therapy in 2017 ( Figure 1 ). While this compilation obviously reflects the personal choices of the editors, it appears to be highly appreciated by the readership, being among the most frequently downloaded articles in both 2016 and 2017. So, in case you missed the original articles, this year's selections cover some of the exciting new advances in the identification of early biomarkers for autism spectrum disorder (ASD), the increased use of fetal sequencing along with its challenges, the expanded genomic targets in non-invasive prenatal testing (NIPT), the anti-angiogenic environment observed in pregnancies complicated by fetal heart disease, advances in fetal surgery techniques, and the accuracy and safety of fetal MRI versus ultrasound examination for the diagnosis of brain anomalies. The selection by no means encompasses all of the exciting advances in our field but serves as a small snippet of the outstanding research carried out by our colleagues.
| EXPANDED NON-INVASIVE PRENATAL TESTING: ADVANTAGES, CHALLENGES, AND UNUSUAL FINDINGS
Noninvasive prenatal testing (NIPT) using cell free fetal DNA has recently expanded to screen for chromosomal abnormalities beyond the common aneuploidies (13, 18, 21 , X, and Y). The expansion has largely been driven by the aspiration to narrow the gap between the scope of anomalies detected by chromosomal microarray analysis (CMA) following CVS/amniocentesis and those screened for by routine NIPT. It is estimated that approximately 17% to 24% of clinically important cytogenetically visible anomalies are not targeted by routine NIPT. 1, 2 In addition, clinically significant sub-microscopic genomic imbalances (CNVs/microdeletions/ microduplications), which are not correlated with maternal age, are seen in approximately 6% of fetuses with structural anomalies and in approximately 1% of cases referred for all other indications. 3 In a recent study of 2779 fetuses that had CMA following invasive prenatal diagnosis, Sotiriadis and colleagues calculated that approximately 50% of the abnormal CMA results would not have been detected by the standard NIPT assays (ie, did not involve trisomies 13, 18, 21, monosomy X, or a sex chromosome trisomy). 4 On the flip side, Pescia et al demonstrated an incremental diagnostic yield of 50% in a study of 6388 consecutive cases screened for an extended range of chromosomal anomalies by genome-wide NIPT. 5 They found rare autosomal trisomies and sub-microscopic imbalances in 0.78% and 0.56% of all cases tested, respectively. 5 For comparison, the common trisomies and sex Dr. Bianchi contributed to this article in her personal capacity. The views expressed are her own and do not necessarily represent the views of the National Institutes of Health or the United States government.
chromosome abnormalities accounted for 1.86% and 0.83% of all cases, respectively.
5 Surprisingly, these rare aneuploidies made up 22.5% of the abnormal cases (excluding microdeletions) and were associated with significant fetal sequelae. 5 A more expansive study of 89 817 pregnancies screened by whole genome NIPT found rare autosomal trisomies in approximately 0.44% of cases. 6 Adverse outcomes were observed in the majority (~75%) of single rare autosomal trisomy cases for which follow-up was available. 6 Negative consequences primarily included an increased risk for feto-placental disease that manifested in multiple ways such as miscarriage, intrauterine fetal death, intrauterine growth restriction, true fetal mosaicism, and uniparental disomy. 6 These single rare trisomies were observed in frequencies comparable to those reported in large CVS studies.
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A challenging possibility associated with the finding of rare autosomal aneuploidies by NIPT is that of maternal cancer. [8] [9] [10] [11] This is particularly likely when single monosomies or multiple rare aneuploidies, which are typically deemed lethal, are seen in an ongoing pregnancy. In a recent study of more than 450 000 NIPT samples, Dharajiya and coworkers found abnormal genomic profiles with multiple aneuploidies in 55 cases and subsequently confirmed the presence of maternal neoplasia in 40 of the 43 cases available for follow-up. 11 Interestingly, half of these involved uterine leiomyomas, which are considered to be benign neoplasms. 11 As such, it is not surprising to learn that for two thirds of patients in the Dharajiya study, the patient was already aware of their cancer. showed the greatest differences between the affected and unaffected groups were the right lingual gyrus, the left and right middle occipital gyri, and the right cuneus. No statistically significant differences were observed in brain cortical thickness. The authors concluded that the hyper-expansion of the cortical surface area might be an early event that leads to generalized brain overgrowth, sensory processing differences, and the autistic behavioral phenotype. Subsequent studies from the same group of investigators suggested that functional neuroimaging of 6-month-old infants at high risk of ASD could predict a diagnosis of autism at 2 years of age. 17 While these data are not necessarily applicable to the fetal brain, they do suggest that deep learning approaches could eventually be applied to MRIs of the fetal brain to identify anatomic markers that could signal a high risk for ASD.
In another important study published this past year, Constantino and colleagues performed eye tracking experiments on 338 toddlers that were designed to measure individual variations in visual attention, specifically viewing of social scenes, with particular attention paid to where on the human face the toddlers gazed. 18 The participant group included 166 twins with known zygosity, 88 singletons with ASD, and 84 singleton controls. The results were striking. Monozygotic twins exhibited extremely high concordance in paying attention to the same or different video stimuli, in the ways in which they sought social information, and in the specific locations on the face at which they fixed their gaze. This is the first time such data have been shown to have such a profound genetic influence. In the cohort of toddlers with ASD, the metrics associated with social and visual engagement were markedly decreased, especially attention to the eyes and the face.
These data provide yet another early potential biomarker for the development of autism.
Due to the rapid pace of research in neurodevelopment, Prenatal Diagnosis dedicated its January 2017 special topic issue to prenatal testing for neuropsychiatric conditions. In this issue, Yin and Schaaf provided an excellent overview of the complex genetics and clinical presentation of ASD. 19 The genetic heterogeneity in autism makes genetic counseling very difficult. The recurrence rate is~23% for a male child and~8% for a female child after 1 affected sibling. This rises considerably after 2 affected siblings:~47% for a male child and 20%
for a female child. 19 There are over 800 genes that predispose to autism. In the 2017 special topic issue, the challenges associated with prenatal genetic counseling for neurodevelopmental disorders were described in a study by Gouvaerts and colleagues. 20 They analyzed outcomes for 57 Dutch fetuses that had been identified as having susceptibility loci for neurodevelopmental disorders following whole genome arrays. Of the 57, 34 had anomalies detected by ultrasound examination and 23 did not. These investigators found that the severity of the sonographic anomalies was the major factor in determining whether or not the parents continued the pregnancy.
With comprehensive genetic counseling, most couples could handle the uncertainties associated with identification of a locus that is sometimes associated with a neurodevelopmental disorder.
| PRENATAL SEQUENCING
One of the highlights of 2017 has been the increasing use of sequencing as an aid to managing pregnancies at risk of genetic disorders, ranging from prenatal screening to the diagnosis of the dysmorphic fetus. A retrospective modeling study of many thousands of carrier screens for 94 single gene disorders suggested that around 1/94 to 1/392 fetuses per 100 000 would be affected, 21 raising the possibility of using extended prenatal carrier screening to identify risk. Subsequently, a small study of parental views showed that if offered preconceptually, over half would opt for PGD, IVF, or prenatal diagnosis in subsequent pregnancies. 22 In 2017, there was an increase in the use of sequencing to determine the genetic etiology in fetuses with congenital anomalies, with a shift from publications reporting small series of highly selected cases in which the diagnostic yield was as high as 80% to reports of larger numbers of unselected cases with much lower diagnostic yields of around 6% to 7%. 23 23, 25, 26 that will be the focus of our 2018 special topic issue. These include the challenges in interpretation of sequencing results in the presence of the more limited phenotypic data available from prenatal imaging. In addition, many prenatal phenotypes are not well described, as they are lethal or evolve through pregnancy. The series also tackles the technical challenges with interpretation, data storage, and coverage of the whole genome. 23, 25 Identification of variants of unknown significance may raise even more uncertainties for parents.
Reporting secondary findings associated with late onset disorders may deny the individual the right to decline this information, and the high costs of sequencing, raising issues of priority setting, are a few of the ethical issues discussed. 26 Many of these sequencing approaches are now available through private providers in the USA 27 This should aid prenatal implementation of this powerful technology.
Non-invasive prenatal testing (NIPT) is now well established
worldwide as a highly sensitive screening test for Down syndrome. 28 Given that epidemiological evidence published in 2017 showed that it is likely that implementation of traditional Down syndrome screening and termination of affected pregnancies has already reduced the birth prevalence of neonates with Down syndrome, 29, 30 there are concerns that NIPT will further reduce this. De Graaf suggests that the initial impact will not be measurable until 2018 due to the inevitable lag in data collection, 31 but Hill and colleagues report that current evidence indicates that rates of termination of pregnancies following a prenatal diagnosis of Down syndrome have remained constant or fallen following implementation of NIPT. 32 They suggest that whilst there may be more prenatal diagnoses of Down syndrome, many parents are using NIPT for information gathering and planning neonatal care, and are continuing pregnancies when Down syndrome is predicted.
| ADVANCES IN DIAGNOSIS AND TREATMENT OF FETAL CARDIAC ANOMALIES
In countries with screening programs for fetal anomalies, the vast majority of fetuses with congenital heart disease (CHD) are now diagnosed prenatally with half of them detected in the first trimester. 33 Improved and earlier diagnosis of fetal heart disease has multiple advantages. First, it advances our understanding of the progression and outcomes of the condition. A recent report from the Eurocat registry shows that approximately 0.7% of fetuses with isolated cardiac defects die before birth. This number increases to 1.8% in "severe" fetal heart disease and reaches close to 5% in those with single ventricle physiology. 34 But prenatal diagnosis also provides better insight into the long-term implications of CHD in those infants who survive. Ultrasound and MRI studies in fetuses with hypoplastic left heart syndrome show that prenatal brain perfusion and oxygenation can be significantly impaired before birth. 35, 36 The latter is a result of the abnormal (retrograde) perfusion of the brain through the aortic duct. A few ground-breaking studies, all published last year, also demonstrated that pregnancies complicated by fetal heart disease display an anti-angiogenic environment, both in the maternal and fetal circulation. Indeed, lower serum placental growth factor levels are already evident in the first trimester in women carrying a fetus with CHD. 37 Low maternal serum placental growth factor and high soluble fms-like tyrosine kinase receptor 1 (s-Flt) have also been reported later in pregnancy. 38 Finally, fetuses with CHD have higher serum s-Flt and soluble Endoglin levels 38 as well as increased s-Flt in the frontal cortex and the basal ganglia of the brain. 39 The combination of suboptimal perfusion with an anti-angiogenic milieu results in alterations in structural brain development in utero, especially in the third trimester.
40,41
The accumulation of data showing abnormal neurodevelopment in fetuses with hypoplastic left heart triggered the International Society for Ultrasound in Obstetrics and Gynecology to release a position statement in 2017 encouraging caregivers to discuss these prenatal findings with expecting couples and to warn them of the potential impact they may have on long-term developmental outcomes. 42 Where early diagnosis of severe CHD, in combination with neurodevelopmental concerns, increases the rate of early pregnancy termination and modifies the spectrum of disease seen in the second trimester, 43 it also paves the path to fetal therapy. In 2017, the Boston group presented their results with in utero valvuloplasty for critical aortic stenosis. 44 After an initial learning curve, technical success rate of this procedure is high (94%), and fetuses that underwent a successful procedure have a reasonable chance of achieving a postnatal biventricular circulation (59%). Fetal valvuloplasty does not, however, seem to improve fetal brain perfusion, 45 nor does it decrease the risk of postnatal neurodevelopmental complications. 46 The Boston group's results were slightly better than those from 2
European studies showing 88% and 74% technical success rates, and biventricular repair rates of 36% and 78%, respectively. 47, 48 Given the lack of randomized trials in this field, it is still unclear whether the outcomes of intervention are better than the natural history of the disease and offset the increased risk of fetal death due to the procedure (6%-36%). 44, 47, 48 Indeed, Gardiner et al recently published a large "natural history" cohort that showed that approximately 1 in 3 fetuses fulfilling the criteria for intra-uterine intervention still had a biventricular postnatal circulation, even without the procedure. 49 As such, fetal aortic valvuloplasty remains experimental, and further refinement of selection criteria or a randomized controlled trial comparing intervention to expectant management with standardized postnatal care are urgently needed.
The same holds true for other fetal cardiac interventions, including septoplasty or stenting of the atrial septum for fetuses with hypoplastic left heart and intact atrial septum, where data of a voluntary international registry show 58% survival rate after intervention, compared to 36% without. 50 
| FETAL SURGERY
Though some trials have shown benefit from prenatal management of the fetus with isolated congenital diaphragmatic hernia (CDH), 51 the controversy will continue as long as the "Tracheal Occlusion To
Accelerate Lung Growth"-trial (www.totaltrial.eu) remains unfinished.
Over 200 fetuses are already included in this study; the moderate trial has recruited over 85% of its calculated sample size. The trial has also grown globally, with centers in the USA (Houston) and Japan (Tokyo)
joining the European and one Australian center(s). Strict criteria for new centers to join apply, so that reproducible lung assessment as well as safety is ensured. [52] [53] [54] Meanwhile research is ongoing on comprehensive assessment of fetuses with isolated CDH, both in terms of predicting lung hypoplasia, pulmonary hypertension, and cardiac function. 55, 56 An increasing number of studies on fetal MR demonstrate how widespread this methodology is, whereas its superiority continues to be uncertain. 57 While fetal spina bifida repair is no longer questioned, the debate has shifted to the access method, the exact surgical technique, and the ethical framework required to introduce alternative techniques. [58] [59] [60] [61] [62] Lately, endoscopic programs in Europe and South America have been joined by programs in the USA. 63 They recently reported on postnatal outcomes in their prospective case series. 64 A minimally invasive approach holds promise for 2 reasons. Firstly, from a maternal perspective, it may lead to lesser uterine scar problems, both in the index as well as the later pregnancies. Secondly, it may reduce membrane rupture rates and preterm delivery, although in a systematic review on early experience this was not the case. 65 MRI diagnoses were made with greater confidence than ultrasound diagnoses, and they were more likely to be subsequently found to be correct. As for the clinical impact, MRI changed the prognostic information in one fifth of cases and had a major influence on counseling in 15% of cases. Whereas ultrasonography showed reduced accuracy with advancing gestation, perhaps owing to increased ossification of the fetal skull, increased maternal size, or descent of the fetal head into the maternal pelvis, the accuracy of MRI was unaffected by gestational age. Although such findings may come as no surprise to many given the 3 published systematic reviews on the subject, this study actually overcomes the methodological weaknesses of the published reviews and highlights the clinical impact on counseling and management. For all its advantages of improved anatomic detail, and less limitation by oligohydramnios, fetal position, or maternal obesity, fetal MRI is still limited by its availability, cost, need for specific expertise, and lower tolerance by patients particularly at advanced gestational ages. A pilot study has explored the feasibility of "fusion imaging," whereby images acquired at MRI are subsequently displayed together with the ultrasound image by the use of dedicated hardware and software, with both sets of images manually synchronized by a second operator. 70 Magnetic navigation allows reformatting of the pre-stored MRI images to match the ultrasound image with voxel-to-voxel correlation. The preliminary data suggest that the new technique has the ability to highlight anatomic areas and subtle anomalies previously not seen at ultrasonography, so that they can be followed up by ultrasonography alone without the need for further MRI scans. Such technology can also take advantage of the additional features offered by ultrasonography, such as superimposed application of color Doppler to document relationship of specific anatomic structures or lesions to the surrounding circulation.
Finally, a large statewide retrospective cohort review of outcomes of 1 424 105 pregnancies including 5654 that underwent MRI in the first trimester of pregnancy has yielded reassuring findings concerning the safety of fetal MRI. 71 Compared with unexposed pregnancies, those exposed to MRI in the first trimester had similar rates of congenital anomalies, fetal death, neoplasm, vision, or hearing loss.
The findings did not change when analysis was restricted to anatomic areas in close proximity to the embryo. In contrast, those exposed to gadolinium-enhanced MRI had higher rates of perinatal deaths (adjusted RR = 3.70, 95% CI 1.55-8.85) and of a combined outcome of any rheumatological, inflammatory, or infiltrative skin condition (adjusted RR = 1.36, 95% CI 1.09-1.69), but similar rates of congenital anomalies.
| CONCLUSIONS
The stimulating research published in 2017 highlights the advances in our field of prenatal diagnosis and therapy. Most importantly, these advances have positively impacted patient care by expanding the diagnostic menu and therapeutic options available during gestation.
As editors, we greatly appreciate the tremendous scope of research that is performed and subsequently submitted for consideration for publication in Prenatal Diagnosis. We encourage you to join our Facebook page to get a real-time glimpse of current issues, posts and events, and perhaps be inspired to leave us constructive insights and feedback. We also encourage you to sign up for our electronic Figure 2 , click on the link to receive these alerts. There is no charge, and you can specify whether or not you want to receive the alerts on a daily, weekly, or monthly basis. You also do not need to be a subscriber to the journal to receive this free service. This is a particularly good way to keep track of the field now that each issue is mainly published electronically.
We look forward to the new submissions in 2018, and wish you all a productive and successful year. 
